UNASSIGNED: Bone is continuously regenerated and remodeled as an adaptation to mechanical load. Bone mass and @entity174 resistance are maintained by a balanced equilibrium between bone formation and bone resorption. Regeneration and response to mechanical load are, however, @entity73 and during aging. Bone resorption is enhanced by chronic @entity32 while bone formation is altered by rising levels of inhibitors in the aging organism. Core molecular principles of the regulation of bone metabolism in health and disease have been characterized and developed as therapeutic targets. The @entity5298 ( @entity5298 ) and osteoclast-derived protease @entity3336 are important regulators and effectors of osteoclast differentiation and bone resorption. Bone formation is stimulated by bone morphogenetic proteins (BMP) and via the parathyroid hormone receptor and the Wnt signaling pathway. The principles of osteoclast inhibition using @entity171 have now been known for almost three decades. Based on more recent knowledge @entity5298 and @entity3336 have been developed as new therapeutic targets to inhibit bone resorption. While denosumab, a @entity5298 antibody, has already been introduced into routine treatment strategies, the @entity3336 antagonist @entity10480 is currently in the licensing process. Bone formation can also be stimulated by local administration of BMPs, by systemic treatment with the parathyroid hormone fragment teriparatide and by using antibodies targeting the Wnt inhibitor sclerostin. The latter are presently being tested in phase III clinical studies. In the near future a panel of traditional and novel treatment strategies will be available that will enable us to meet the individual clinical needs during aging and for the treatment of @entity170 .

[Regulation of bone metabolism in @entity170 : Novel drugs for XXXX in development].

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity3336 :: ('1513', 'Gene') :: ['cathepsin K'] @entity171 :: ('MESH:D004164', 'Chemical') :: ['bisphosphonates'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture'] @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired in osteoporosis'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity5298 :: ('8600', 'Gene') :: ['receptor activator of nuclear factor kappaB ligand', 'RANKL'] @entity10480 :: ('MESH:C527128', 'Chemical') :: ['odanacatib']
@entity170 :: (MESH:D010024,Disease) :: ['osteoporosis']
